Holen Sie sich die Stockscreener-App
0.3903
7.34%
0.0267
Schlusskurs vom Vortag:
$0.3636
Offen:
$0.37
24-Stunden-Volumen:
80,883
Relative Volume:
0.07
Marktkapitalisierung:
$5.20M
Einnahmen:
$72,100
Nettoeinkommen (Verlust:
$-3.60M
KGV:
-0.328
EPS:
-1.19
Netto-Cashflow:
$-3.37M
1W Leistung:
-5.54%
1M Leistung:
-32.13%
6M Leistung:
-12.39%
1J Leistung:
-57.11%
1-Tages-Spanne:
$0.3601
$0.3998
1-Wochen-Bereich:
$0.3601
$0.47
52-Wochen-Spanne:
$0.3601
$3.3699
Silo Pharma Inc Stock (SILO) Company Profile
Firmenname
Silo Pharma Inc
Sektor
Branche
Telefon
(718) 400-9031
Adresse
677 N. WASHINGTON BLVD, SARASOTA
Vergleichen Sie SILO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
2.15 | 3.06B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.51 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.15 | 166.65M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.22 | 492.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
0.72 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Aktie (SILO) Neueste Nachrichten
Silo Pharma CEO Weisblum buys $735 in company stock By Investing.com - Investing.com Australia
[Form 4] Silo Pharma, Inc. Insider Trading Activity - Stock Titan
Silo Pharma CEO Weisblum buys $735 in company stock - Investing.com
Will earnings trigger a reversal in Silo Pharma Inc.Market Risk Report & Smart Investment Allocation Tips - newser.com
Is Silo Pharma Inc. stock attractive for long term wealth buildingEntry Point & Long-Term Safe Return Strategies - newser.com
Is now a turning point for Silo Pharma Inc.July 2025 Analyst Calls & Accurate Intraday Trade Tips - newser.com
Silo Pharma selects Allucent to support PTSD treatment IND submission By Investing.com - Investing.com Nigeria
Evaluating Silo Pharma Inc. with trendline analysisMarket Rally & Weekly Stock Performance Updates - newser.com
Silo Pharma selects Allucent to support PTSD treatment IND submission - Investing.com
Silo Pharma partners with Allucent to support planned FDA Investigational New Drug application for SPC-15 as a therapeutic for PTSD - MarketScreener
Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd - TradingView
Silo Pharma (Nasdaq: SILO) taps Allucent to advance SPC-15 PTSD intranasal IND prep - Stock Titan
Can Silo Pharma Inc. stock deliver strong Q4 earningsNew Guidance & Free Safe Entry Trade Signal Reports - newser.com
Will Silo Pharma Inc. rebound enough to break evenExit Point & Weekly Watchlist for Hot Stocks - newser.com
Combining price and volume data for Silo Pharma Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What drives Silo Pharma Inc stock priceInsider Buying Signals & Low Risk Capital Growth - earlytimes.in
[10-Q] Silo Pharma, Inc. Quarterly Earnings Report | SILO SEC FilingForm 10-Q - Stock Titan
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
What analysts say about Silo Pharma Inc stockEx-Dividend Date Alerts & Maximize ROI With Proven Growth Stocks - earlytimes.in
How strong is Silo Pharma Inc. stock revenue growthJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
Silo Pharma announces pricing of $2 million public offering - MSN
Is Silo Pharma Inc. showing signs of accumulationEarnings Risk Report & Consistent Profit Focused Trading Strategies - newser.com
How analysts rate Silo Pharma Inc. stock todayTrade Ideas & Consistent Return Investment Signals - Fundação Cultural do Pará
Finanzdaten der Silo Pharma Inc-Aktie (SILO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):